ROLE OF SOMVALK KASHAY ASTHAPAN BASTI IN PRAMEHA W.S.R TO (DIABETES MELLITUS TYPE 2)

The disease diabetes currently affects more than 62 million people which is more than 7.1% of India’s adult population. The prevalence rate of diabetes in urban and rural areas is 10.3% and 6.2% respectively. The Aim of the study is standardization of the method of preparation and administration of Somvalk Kashay Asthapan Basti and Somvalk Siddha Taila Anuvasan Basti. Two groups Group A (Trial Group) 50 patients is given Somvalkkashayasthapan Basti, and Somvalk siddhataila anuvasanbasti along with Metformin for 12 days and Group B (Control Group) 50 patients is given oral hypoglycemic drug and Metformin will be given according to the dosage 12 days. Group A showed moderate improvement, while Group B showed no improvement. The overall result obtained in the present study  shows 65% improvement in trial group which is moderate improvement according to the overall assessment criteria, whereas there was only 18% improvement in the control group which falls within unimproved category according to the overall assessment criteria. The trial drug in the study i.e., Somvalk kasha Asthapanbasti has been proved significantly effective in symptoms like Polyuria, polydipsia, polyphagia and urine sugar. It has shown moderate effects on the symptoms like numbness and tingling. It has shown mild improvement in parameters of BSL- Fasting and BSL- PP

LITERARY STUDY OF MUTRASANGRAHANIYA MAHAKASHAYA WITH RESPECT TO MUTRASANGRAHANIYA KARMA

The tremendous craze for junk food, fast food, canned food, untimely food intake wrong sleeping habits, causes physical as well as mental hazards like Sheetmeha, Hastimeha, hypertension along with that Insomnia, Anxiety etc. have become a very common problem.The herbal option for treatment of Sheetameha, Hastimeha etc. Mutrasangrahaniya Mahakashaya from Ayurvedic text can be used as readymade guide. In this work Mutrasangrahaniya Mahakashaya from Charak Samhita is studied. Prameha is considered as one of the emerging disease in today’s era. The cardinal symptom of Prameha in Ayurveda is Atipravrutti of Mutra which resemble to the “Diabetes”.Numerous Experiments and Research projects are performed everyday to tackle this disease. So it is very much essential to learn & understand the drugs which are crucial & can act as to key drugs in such diseases. So it is very much required to study Mutrasangrahaniya Karma. The Dravyas used for Mutrasagrahaniya Karma are mainly Kashaya rasatmaka which control the Atipravrutti of Mutra by absorbing Jaliyansh.Mutrasangrahana Karma can be defined as the activity that reduced the amount of Mutra thus restoring the normally of Ambu. Jambu, Amra, Plaksa, Udumbara, Ashvattha, Bhallataka, Vata, Asmantaka, Kapitana, Somvalka are ten herbs of Mutrasangrahaniya Mahakashaya and their Karmukatva as mentioned mainly in Charaka Samhita and if necessary, other ancient texts. These ten Dravyas mainly have Kashaya rasa, Sheeta virya, Ruksha guna and are Kapha pitta shamaka. They help in rectifying Atipravrutti of Mutra by directly and indirectly

Fabrication and evaluation of mannose decorated curcumin loaded nanostructured lipid carriers for hepatocyte targeting: In vivo hepatoprotective activity in Wistar rats

Curcumin is a well-recognized antioxidant phytoactive isolated from the rhizomes of Curcuma longa. Numerous landmark investigations have proved the antioxidant and hepatoprotective potential of curcumin. The aim of present study was to target curcumin loaded nanocarriers to hepatocytes using asialoglycoprotein receptors targeting strategy. Mannose, a water-soluble carbohydrate, was hydrophobized by anchoring stearylamine with an objective to conjugate mannose on the surface of curcumin loaded nanostructured lipid carriers for targeting asialoglycoprotein receptors on hepatocytes. Mannose conjugated stearylamine was synthesized and characterized using various analytical techniques. The synthesized targeting ligand was incorporated curcumin loaded nanostructured lipid carriers and characterized by photon correlation spectroscopy. Zeta potential measurement was used to confirm the conjugation of the synthesized ligand to the surface of drug-loaded nanostructured lipid carriers. CCl4 induced hepatotoxicity in male Wistar rats was used as an experimental animal model to evaluate the hepatoprotective potential of formulated drug encapsulated nanostructured lipid carriers. The hepatoprotective potential was assessed by measuring serum liver injury markers and oxidative stress parameters in the liver post–mitochondrial supernatant. Mannose conjugated nanostructured lipid carriers showed acceptable particle size which revealed its suitability for hepatocyte targeting. In addition to this, mannose conjugated nanocarriers revealed significantly better (p ​< ​0.05) reduction of serum liver injury markers and proinflammatory cytokines compared to the unconjugated one which confirmed hepatocytes targeting potential of the synthesized ligand. Asialoglycoprotein receptors targeting could be a landmark strategy for hepatocyte targeting. Thus, the synthesized mannose anchored stearylamine could be a promising novel targeting ligand having hepatocyte targeting potential